Temozolomide (NSC 362856), DNA Alkylator
Por um escritor misterioso
Descrição
Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects. - Mechanism of Action & Protocol.
Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies
Temozolomide American Journal of Cancer
Biomedicines, Free Full-Text
In search of effective therapies to overcome resistance to Temozolomide in brain tumours
Crosstalk between repair pathways elicits double-strand breaks in alkylated DNA and implications for the action of temozolomide
Novel strategies of Raman imaging for monitoring the therapeutic benefit of temozolomide in glioblastoma - ScienceDirect
Temozolomide (NSC 362856), DNA Alkylator
A Randomized, Open-Label, Two-Way Crossover, Single-Dose Bioequivalence Study of Temozolomide 200 mg/m2 (Dralitem® vs. Temodal® Capsules) in Patients with Primary Tumors of the Central Nervous System Under Fasting Conditions
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers - ScienceDirect
Frontiers An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
